Latest Capital Raise News

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Gryphon Capital Income Trust reported a robust half-year profit increase alongside successful capital raises, positioning the fund for expanded investment in Australian RMBS and ABS markets.

Echo IQ Limited reported a modest revenue increase for the half-year ended December 2025, yet its net loss widened significantly, raising questions about its path to profitability.

Beonic Limited reported a 5.5% revenue increase to $11.2 million and reduced its net loss to $1.44 million for the half-year ending December 2025. The company also repaid a $4.65 million loan and secured a major $7.3 million contract to deploy passenger flow management solutions across seven Moroccan airports.

Decidr AI Industries Ltd reported a $17.2 million loss for the half-year ending December 2025, reversing a prior profit, while completing full ownership of Decidr.ai and expanding into the US market with Sugarwork Inc.

BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.

Australian Dairy Nutritionals Group has cut its net loss by 40% in the half-year to December 2025, driven by a remarkable 431% revenue jump in its nutritional powders segment amid expanding Chinese distribution.

Alpha HPA Limited reported a $22.5 million loss for the half-year ending December 2025, driven by ongoing investment in its HPA First Project. Despite the loss, strong demand from semiconductor and battery sectors and a recent $225 million capital raise position the company for significant growth.

NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.

Pengana Global Private Credit Trust reported a robust half-year performance with $7.5 million net profit and a stable NAV of $2.00 per unit, supported by a $69 million capital raise and an 8.9% annual yield. Despite increased market volatility, the Trust’s diversified private credit portfolio remains resilient.